Objective: To quantify gait abnormalities in people with Dravet syndrome (DS).Methods: Individuals with a confirmed diagnosis of DS were enrolled. They were stratified according to knee flexion at initial contact (IC) and range of motion (ROM) during stance [crouch gait if knee flexion >20° at IC and knee range of motion (ROM) >15°; straight gait: knee flexion <20° at IC]. A 1D ANOVA (α = 0.05) was used to test statistical differences among the joint kinematics and spatio-temporal parameters of the cohort and an age-matched control group. Clinical (neurological and orthopedic evaluation) and anamnestic data (seizure type, drugs, genetic mutation) were collected; distribution between the two gait phenotypes was assessed with the Fisher exact test and, for mutation, with the chi-squared test (p-value < 0.05).Results: Seventy-one subjects were enrolled and evaluated with instrumented gait analysis. Fifty-two were included in the final analysis (mean age 13.8 ± 7.3; M 26). Two gait patterns were detected: an atypical crouch gait (34.6%) with increased ankle, knee and hip flexion during stance, and reduced walking speed and stride length without any muscle-tendon retraction; and a pattern resembling those of healthy age-matched controls, but still showing reduced walking speed and stride length. No difference in clinical or anamnestic data emerged between the two groups.Significance: Objectively quantified gait in DS shows two gait patterns with no clear-cut relation to clinical data. Kinematic parameters abnormalities are likely due to stabilization issues. These findings may guide rehabilitative and preventive measures.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.